Theravance To Split To Create Firm Focused On GSK Tie-Up

Law360, New York (April 26, 2013, 4:14 PM EDT) -- Biopharmaceutical firm Theravance Inc. will be split into two independent publicly traded firms, one of which will work with British pharmaceutical giant GlaxoSmithKline PLC on their ongoing collaboration to develop certain respiratory drugs, Theravance said Thursday.

The split firms are currently labeled Royalty Management Co., which will work with GSK, and Theravance Biopharma, a biopharmaceutical firm that will develop small-molecule medicines — some of the most common drugs which come in the form of pills, such as painkillers — according to a statement by Theravance. ...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.